Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Key Highlights
- ➤Cash $140.7M, up from $31.6M, extends runway into 2H 2029
- ➤Ciprocopan approved in China for previously untreated PNH patients
- ➤NXP200 high-grade glioma ORR 40.0%, including three complete responses
- ➤Nuvectis raised $115.0M through a July follow-on offering
- ➤Third-quarter net loss $30.1M, including $20.0M upfront licensing payment
Expert Statements
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“The last few months have been truly transformational for Nuvectis”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“Our immediate priority is to advance ciprocopan toward a U.S. marketing application in PNH, as well as in additional indications.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“Our discussions with the FDA regarding the next steps for PNH are well underway, and we expect to provide an update before year-end.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“We plan to submit a U.S. IND for NXP100 by year-end.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“In parallel, we are building out our internal complement expertise to support a broad development program.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“For NXP200, updated Phase 1b results in BRAF V600-mutated recurrent or progressive glioma were presented at the recent ESMO annual meeting.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“Single-agent NXP200 demonstrated durable responses, including complete responses, with activity also seen in patients previously treated with a BRAF inhibitor.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“The data are encouraging and underscore the potential of NXP200 to become a differentiated, best-in-class, second-generation, paradox-breaker BRAF inhibitor.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“We expect to submit a U.S. IND for NXP200 by year-end, and we look forward to providing additional NXP200 Phase 1b data from China, alongside a Phase 1b data update for NXP900, our SRC-Yes1 kinase inhibitor, in the coming months.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“We ended the quarter with approximately $140 million in cash, representing the strongest financial position in Nuvectis’ history.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“We expect this funding to support our operations into the second half of 2029, providing a runway that extends well beyond multiple potential value-creating clinical and regulatory milestones.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“We welcome Dustin to Nuvectis.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“Dustin has had an immediate impact on the NXP100 program including involvement in the FDA discussions for PNH, conducting prioritization assessments of other indications, protocol writing and interactions with top key opinion leaders.”
Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis
“Dustin’s knowledge and understanding of the complement inhibition in nephrology and hematology diseases are exceptional and we look forward to harnessing his expertise as we set out to establish NXP100 as a potential best-in-class compound across several indications.”
Dustin Little, Senior Vice President, Head of the Complement program at Nuvectis
“It’s exciting to join Nuvectis at such a transformative time.”
Dustin Little, Senior Vice President, Head of the Complement program at Nuvectis
“The company has built a strong foundation and NXP100, as a late-stage once-a-day oral CFBi, represents a unique opportunity for significant impact across several indications.”
Dustin Little, Senior Vice President, Head of the Complement program at Nuvectis
“Leveraging my industry experience and medical knowledge, I look forward to helping spearhead this program forward while utilizing the compelling NXP100 Chinese and other CFBi data as a roadmap for our development plans.”
* In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. * The Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor (CFBi) for once-daily oral administration, was approved in China in July 2026 for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with complement inhibitors.
FDA discussions ongoing regarding the U.S. regulatory path forward for ciprocopan in patients with PNH; An update is expected before year-end. * Cash position of approximately $140 million extends the Company’s runway into 2H 2029. Nuvectis will hold a conference call today at 8:00 AM ET to discuss business highlights and its third quarter 2026 financial results.
Get started
Create a free account to read the full story.